Egypt at a glance
- Population
- 118.4 million 2025
- Life expectancy at birth
- 71.8 years, 2024
- People aged 65 and over
- 5.3 % of people, 2025
- Health spending per person
- 141 US$ per person, 2023
- Doctors
- 0.67 per 1,000 people, 2020
Updated
Reviewed by Chandani Patel
Egypt Gene Therapy for Hemophilia Market Industry Trends and Forecast to 2034: Segmented by (Type, Vector, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$16.6 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $1.2 Mn | — | — |
| 2025 (base) | $1.6 Mn | +$0.4 Mn | — |
| 2026 (forecast) | $2.0 Mn | +$0.5 Mn | +31.4% |
| 2027 (forecast) | $2.7 Mn | +$0.6 Mn | +72.7% |
| 2028 (forecast) | $3.5 Mn | +$0.8 Mn | +126.9% |
| 2029 (forecast) | $4.6 Mn | +$1.1 Mn | +198.1% |
| 2030 (forecast) | $6.1 Mn | +$1.5 Mn | +291.7% |
| 2031 (forecast) | $8.0 Mn | +$1.9 Mn | +414.7% |
| 2032 (forecast) | $10.5 Mn | +$2.5 Mn | +576.3% |
| 2033 (forecast) | $13.8 Mn | +$3.3 Mn | +788.7% |
| 2034 (forecast) | $18.1 Mn | +$4.3 Mn | +1,067.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $1.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $18.1 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 31.4% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Type, vector and end user (see all) |
| Key players | BioMarin, CSL Behring, Pfizer Inc., Roche, Sangamo Therapeutics (see all) |
| Regulator in Egypt | EDASource: Egyptian Drug Authority. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Gene therapies for hemophilia give patients a working copy of the clotting factor gene, so they may need fewer or no regular infusions.
Key segments of the gene Therapy for Hemophilia market include type (Hemophilia A and Hemophilia B) and vector (AAV5 and AAV Other Serotypes).
Approvals of the first curative gene and cell therapies, strong investment in biotech, better manufacturing and growing evidence in rare and blood diseases are driving the gene Therapy for Hemophilia market.
Allogeneic (off-the-shelf) products, in-vivo delivery and use in common diseases open large growth for the gene Therapy for Hemophilia market.
Very high prices, complex manufacturing, limited treatment centres and uncertain long-term safety hold back the gene Therapy for Hemophilia market. Payers are still working out how to pay for one-time cures.
The gene Therapy for Hemophilia market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicines are registered with the Egyptian Drug Authority (EDA), set up in 2019.[1] A universal health insurance system, set up by Law No. 2 of 2018, is being rolled out governorate by governorate, starting with Port Said in 2019.[2]
[1] Egyptian Drug Authority. Checked 14 Nov 2026.
[2] Universal Health Insurance Authority. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for gene Therapy for Hemophilia. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Egypt.
What doctors and scientists are doing in Gene Therapy for Hemophilia right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 22 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 22 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 22 Nov 2026.
Egypt · 2 shared keywords
Egypt
Egypt
Egypt
Egypt
Egypt
OTC & Nutraceuticals · Egypt
Healthcare Services · Egypt
Medical Devices · Egypt
Medical Devices · Egypt